|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Alnylam gapped up Wednesday — to Ionis' detriment — after reporting positive results in a late-stage trial of a drug to treat a rare disease.
Novartis expects the next growth phase to begin in 2018 driven by Cosentyx Entresto, Kisqali and Kymriah.
Phase 3 trials of Alnylam's patisiran were a success, paving the way to an FDA filing for approval later this year.